BioXcel Therapeutics Ownership | Who Owns BioXcel Therapeutics?


OverviewForecastRevenueFinancialsChart

BioXcel Therapeutics Ownership Summary


BioXcel Therapeutics is owned by 7.01% institutional investors, 4.21% insiders, and 88.78% retail investors. Oaktree capital management lp is the largest institutional shareholder, holding 3.08% of BTAI shares. BSO Bio Santé C is the top mutual fund, with 2.26% of its assets in BioXcel Therapeutics shares.

BTAI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBioXcel Therapeutics7.01%4.21%88.78%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Oaktree capital management lp241.19K3.08%$617.44K
Fmr198.60K2.53%$508.42K
Vanguard group192.13K2.45%$491.84K
Geode capital management125.24K1.60%$320.62K
Xtx topco113.36K1.45%$290.21K
Blackrock440.69K1.43%$564.08K
Blackrock funding, inc. /de84.28K1.07%$215.76K
State street52.72K0.67%$134.96K
Charles schwab investment management203.62K0.66%$260.63K
Ubs group43.54K0.56%$111.47K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Oaktree fund advisors42.91K0.20%$109.86K
Slt29.50K0.05%$75.52K
Xtx topco113.36K0.02%$290.21K
Oaktree capital management lp241.19K0.01%$617.44K
Diversify wealth management15.00K0.00%$28.50K
Foundations investment advisors29.55K0.00%$75.64K
Tower research capital llc (trc)3.93K0.00%$10.07K
Allsquare wealth management175.000.00%$317.00
Jones financial companies lllp36.00K0.00%$97.20K
Hightower advisors35.00K0.00%$89.60K

Top Buyers

HolderShares% AssetsChange
Fmr198.60K-198.60K
Vanguard group192.13K-173.30K
Geode capital management125.24K-97.06K
Xtx topco113.36K0.02%89.94K
Goldman sachs group98.97K-76.20K

Top Sellers

HolderShares% AssetsChange
Armistice capital---4.32M
Blackrock440.69K--887.38K
Ameriprise financial---579.16K
Bank of new york mellon---123.08K
Millennium management---104.97K

New Positions

HolderShares% AssetsChangeValue
State street52.72K-52.72K$134.96K
Northern trust37.73K-37.73K$96.60K
Foundations investment advisors29.55K0.00%29.55K$75.64K
Slt29.50K0.05%29.50K$75.52K
Aqr capital management14.36K-14.36K$18.38K

Sold Out

HolderChange
Mount yale investment advisors-1.00
Federation des caisses desjardins du quebec-1.00
Nelson, van denburg & campbell wealth management group-4.00
Farther finance advisors-5.00
National bank of canada /fi/-6.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202516-51.52%549,847-11.04%711.29%10-33.33%1-85.71%
Jun 30, 2025323.23%613,02561.47%7797.16%14100.00%7-70.83%
Mar 31, 20251-97.92%661-99.99%-0.85%1-94.74%--100.00%
Dec 31, 202413-74.00%537,273-82.68%12.37%4-63.64%6-77.78%
Sep 30, 202450-33.33%3,102,869-68.25%70.73%12-72.73%2750.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
BSO Bio Santé C70.00K2.26%-
Vanguard Total Stock Mkt Idx Inv55.39K1.73%-
Fidelity Growth Compy Commingled Pl O469.48K1.15%-425.27K
Vanguard US Total Market Shares ETF886.24K1.01%-1.00
Fidelity Growth Company Fund353.64K0.87%-248.67K
Vanguard Institutional Extnd Mkt Idx Tr43.45K0.66%25.12K
Fidelity Growth Company K6163.94K0.40%-132.22K
Fidelity Series Growth Company88.26K0.22%-63.60K
Fidelity Extended Market Index27.57K0.17%13.34K
NT R2000 Growth Index Fund - NL57.60K0.14%-

Recent Insider Transactions


DateNameRoleActivityValue
Dec 16, 2024O'Neill Vincent See RemarksSell$58.13
Dec 16, 2024Mehta Vimal CEO and PresidentSell$773.36
Dec 16, 2024Mehta Vimal CEO and PresidentSell$357.91
Dec 16, 2024Steinhart Richard I Chief Financial OfficerSell$73.80
Dec 16, 2024Steinhart Richard I Chief Financial OfficerSell$133.18

Insider Transactions Trends


DateBuySell
2025 Q4--
2025 Q3--
2025 Q2--
2025 Q1--
2024 Q4-12

BTAI Ownership FAQ


Who Owns BioXcel Therapeutics?

BioXcel Therapeutics shareholders are primarily institutional investors at 7.01%, followed by 4.21% insiders and 88.78% retail investors. The average institutional ownership in BioXcel Therapeutics's industry, Biotech Stocks , is 45.22%, which BioXcel Therapeutics falls below.

Who owns the most shares of BioXcel Therapeutics?

BioXcel Therapeutics’s largest shareholders are Oaktree capital management lp (241.19K shares, 3.08%), Fmr (198.6K shares, 2.53%), and Vanguard group (192.12K shares, 2.45%). Together, they hold 8.06% of BioXcel Therapeutics’s total shares outstanding.

Does Blackrock own BioXcel Therapeutics?

Yes, BlackRock owns 1.43% of BioXcel Therapeutics, totaling 440.68K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 564.08K$. In the last quarter, BlackRock decreased its holdings by -887K shares, a -66.82% change.

Who is BioXcel Therapeutics’s biggest shareholder by percentage of total assets invested?

Oaktree fund advisors is BioXcel Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.20% of its assets in 42.91K BioXcel Therapeutics shares, valued at 109.86K$.

Who is the top mutual fund holder of BioXcel Therapeutics shares?

BSO Bio Santé C is the top mutual fund holder of BioXcel Therapeutics shares, with 2.26% of its total shares outstanding invested in 70K BioXcel Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools